Drug Profile
ETC 276
Alternative Names: ProApo A-1; Proapolipoprotein A-1Latest Information Update: 10 Dec 2007
Price :
$50
*
At a glance
- Originator Esperion Therapeutics
- Class Antihyperlipidaemics
- Mechanism of Action Apolipoprotein A I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 31 Dec 2002 Suspended - Phase-I for Atherosclerosis in USA (IV)
- 24 Nov 2000 Phase-I clinical trials for Atherosclerosis in USA (IV)
- 24 Feb 2000 Preclinical development for Atherosclerosis in USA (IV)